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Abstract: The presence of suicidal manifestations (thoughts and behavior) was studied in 
a cohort of 30 patients with mild to moderate depression during a 6-week treatment with the 
serotonin-norepinephrine reuptake inhibitor, milnacipran. At baseline mild suicidal thoughts 
were present in 46.7% of patients, the mean Hamilton Depression Rating Score (HDRS17) was 
23.9 ± 1.8 and the mean suicidality score on the Beck Scale for Suicidal Ideation (BSS) was 
4.9 ± 4.9. Suicidal thoughts decreased progressively throughout the study in parallel with other 
depressive symptoms. At no time during treatment was there any indication of an increased 
suicidal risk. Notably, the items retardation and psychic anxiety on the HDRS17 decreased in 
parallel. This may possibly explain the lack of any “activation syndrome”, which is occasion-
ally observed at the early stages of therapy with some antidepressants and may be linked to 
a temporary increase in suicidal ideation. To our knowledge this is the first detailed report of 
suicidality during treatment with milnacipran.
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Introduction
There is a clear association between suicide and depression. Mood disorders, principally 
major depressive disorder and bipolar disorder, are associated with about 60% of all 
suicides.1–6 An often-quoted figure is that about 15% of patients with major depression 
will eventually die by suicide.7,8 This estimation is, however, derived largely from 
studies of severely depressed inpatients. More recently a more conservative lifetime 
suicide risk in the general population of depressed patients of about 6% has been 
calculated.9 This discrepancy has been erroneously interpreted by many primary care 
physicians and certain psychiatrists as evidence that overt suicidal behavior occurs 
only in severe depression. This notion can lead to inappropriate management of less 
severely depressed patients.
The more recent clinical literature clearly supports the idea that suicidality (thoughts 
and behavior) is associated with any type of depressive disorder and any degree of 
severity.10,11 Antidepressant therapy, which is effective in managing the symptoms of 
major depressive disorder, is expected to reduce or prevent suicidal behavior associated 
with depression.12,13 This hypothesis has been questioned, however, by large multi-study 
analyses that have suggested that, at least in certain patients groups, antidepressants 
may enhance or even induce suicidal ideation.14,15 In 2004 the US Food and Drug 
Administration warned of the possible enhancement of suicidal ideation in pediatric and 
adult patients receiving modern antidepressants especially at the beginning of therapy Neuropsychiatric Disease and Treatment 2009:5 416
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and at dose increase. This interpretation is controversial and 
the results of other meta-analyses16,17 have not supported the 
enhancement of suicidal ideation in adult patients with short-
term antidepressant treatment compared to placebo. The 
latest analyses indicated that patients receiving SSRIs and 
tricyclic antidepressants (TCAs) do not show significantly 
more suicidality than patients receiving placebo.6,18 Indeed 
several studies have shown that suicide rates have decreased 
since the introduction of modern antidepressants supporting 
the hypothesis that the use of antidepressants may prevent 
suicide.19,20
In the light of this controversy, the effect of an antide-
pressant, especially a recently introduced one, on suicidal 
ideation clearly remains an important question. Thus, in 
addition to assessing the general efficacy and tolerability 
of milnacipran (Ixel®), a serotonin and norepinephrine 
reuptake inhibitor (SNRI)21 recently introduced into Russia, 
the primary aim of the present investigation was to observe 
the effects of the drug on the occurrence and intensity 
of suicidal thoughts and behavior in patients with mild 
to moderate depressive disorders and to assess whether 
suicidality decreased in parallel with other depressive 
symptoms.
Methods
The investigation was a 6-week open label study in patients 
enrolled from an outpatient clinic (Psychiatric Hospital N12) 
in Moscow. Inclusion criteria were: age 16 to 65 years, 
a diagnosis of mild to moderate depression which could 
be either a single depressive episode, recurrent depressive 
disorder, bipolar disorder, dysthymia, cyclothymia, con-
tinuous depressive reaction within an adaptation disorder 
or other mood disorder. Exclusion criteria included severe 
depression with psychotic manifestations; schizophrenia 
and schizoaffective disorder; abuse of alcohol and other 
psychoactive agents; pronounced manifestations of psycho-
organic syndrome (or chronic brain disorder), including 
paroxysmal disorders; severe or decompensated somatic 
pathology requiring continuous polypharmacotherapy; 
pregnancy and lactation; participation in clinical trials within 
30 days prior to start-up of the present study; and contradic-
tions to milnacipran treatment. All diagnoses were based on 
ICD-10 criteria.
The study was approved by the local ethics committee 
and was carried out in accordance with the Declaration of 
Helsinki. All patients gave their written informed consent.
In addition to a standard psychiatric and general 
clinical examination (including urinalysis, hematology and 
biochemistry, electrocardiogram), the 17-item Hamilton 
Depression Rating Scale (HDRS17), Clinical Global Impres-
sion (CGI), Beck Depression Inventory (BDI), Beck Scale 
for Suicidal Ideation (BSS)22 and the Udvalg for Kliniske 
Undersøgelser Side Effect Rating scale (UKU-side-effects) 
were used.
Milnacipran was administered initially, for 2 to 3 days, 
at 25 to 50 mg/day depending on the severity of depres-
sive symptoms. If the drug was well tolerated the dose was 
increased to 100 mg/day (50 mg twice daily).
The statistical significance of changes from baseline dur-
ing the study were determined using paired Student’s t-test 
and Wilcoxon nonparametric test using the statistical and 
analytical software package STATISTICA. The significance 
level was set as P  0.05
Results
Thirty patients were enrolled in the study. Demographic 
characteristics of the patients are shown in Table 1. Women 
Table 1 Patients’ clinical demographics
N %
Female/Male 26/4 86.7/13.3
Mean age (yr) 41.4 ± 9.6
highest education level higher 18 60
secondary 10 33.3
Primary 2 6.7
Professional activity employed 18 60
Unemployed 12 40
Marital status Married 12 40
Unmarried 18 60
Diagnosis (icD-10) single major 
depressive episode
18 60
Recurrent major 
depressive disorder
12 40
Type of depression Apathetic 10 33.3
Anxious 6 20
Asthenic 6 20
hysteric 6 20
hypochondriac 2 6.7
Severity of current episode
Total Mild 4 13.3
Moderate 26 86.7
single episode Mild 2
Moderate 16
Recurrent episode Mild 2
Moderate 10Neuropsychiatric Disease and Treatment 2009:5 417
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comprised 86.6% of the cohort and the mean age of patients 
was 41.4 ± 9.5 (all values are given as mean ± standard 
deviation). In general the educational level was high with 60% 
of patients having a higher (university) education and 33.3% 
a secondary education. Only 40% of patients were married.
The majority of patients (60%) had a diagnosis of a single 
depressive episode. Most patients (86.6%) at baseline were 
considered to be moderately depressed. The baseline HDRS17 
was 23.9 ± 1.8 and BDI was 37.7 ± 3.9. The apathetic form 
of depression was the most frequent while anxious, asthenic 
and hysteric forms were also common. The hypochondriac 
form was only found in 2 patients.
Two patients withdrew from the study, one at the end of 
the first week of treatment because of adverse events (nausea) 
and the other at the end of the 4th week of treatment due to 
lack of efficacy of the treatment.
Antidepressant efficacy
The efficacy of the antidepressant treatment was demon-
strated by the steady reduction of the mean HDRS17 score 
throughout the study (Figure 1). Statistically significant 
differences compared to baseline occurred from the first 
week of therapy. At endpoint (after 6 weeks treatment) mean 
HDRS17 was 9.5 ± 4.4 and 60% of patients were treatment 
responders (reduction of baseline HDRS17 of at least 50%). 
BDI scores showed a similar progressive reduction with a 
significant difference (P  0.05) from baseline occurring 
from the third week of treatment. The mean BDI score at 
endpoint was 21.4 ± 6.1 (data not shown).
The mean baseline score on the CGI (Severity) scale was 
3.9 ± 0.4 indicating a moderate severity. This value decreased 
progressively with a significant difference (P  0.05) from 
baseline occurring after 3 weeks of treatment. At endpoint 
the mean CGI (Severity) score was 2.1 ± 0.3, indicating 
borderline depression (data not shown).
Suicidality
At baseline mild suicidal ideation was found in 14 patients 
(46.7%). No current or previous suicidal attempts, planning 
or preparation were noted in any patient.
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Figure 1 Reduction of mean global hDRs17 scores during the study.
Notes: *P  0.05; **P  0.01 compared to baseline values. 
Abbreviations: B, baseline;   W1 to W6, number of weeks of treatment.Neuropsychiatric Disease and Treatment 2009:5 418
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A total of 57 suicidal manifestations were found during 
the study (Table 2). The most common suicidal manifesta-
tions were thoughts of “inanity of existence”, thoughts that 
death could resolve existing sufferings, suicidal thoughts and 
unwillingness to live.
More rarely, different signs of suicidality were reported: 
visualization of own suicide, death or funeral, as well as 
(supraliminal) death instinct. Only in a few patients did these 
suicidal ideations develop into either ideational compulsions 
(compulsive thoughts and concepts of death and funerals) 
or suicidal fantasies. Suicidal compulsive thoughts and con-
cepts developed in patients with asthenic and hypochondriac 
depression, and suicidal fantasies in patients with hysteric 
depression. No other relationships, including those between 
suicidal phenomena and patients personality characteristics 
were detected.
The entry criteria of this study allowed the recruitment of 
patients with a single depressive episode, recurrent depres-
sive disorder, chronic depression, bipolar disorder, dysthymia 
or cyclothymia. Unfortunately subanalysis of the different 
types of depression was not possible due to the small numbers 
of each subtype.
Mean baseline BSS score was 4.9 ± 4.9, indicating a 
mild level of suicidality in this group of patients. Suicidal-
ity decreased rapidly with a significant reduction observed 
from the second week of treatment (Table 3). After 4 weeks 
of treatment, mean BSS scores were close to zero indicat-
ing an absence of any suicidal activity in treated patients. 
None of the patients showed any increase in BSS score 
during milnacipran treatment indicating an absence of any 
“activation syndrome”, sometimes observed at the early 
stages of therapy with certain antidepressants.10
Analysis of the “suicidal thoughts/attempts” item of 
the HDRS17 at baseline showed a score of 1 in 10 patients 
(33.3%) and of 2 in one patient. The number of patients 
with scores 1 or 2 decreased progressively throughout the 
study. At endpoint only 3 patients had a score of 1, all others 
scoring zero.
The HDRS17 items of “psychic anxiety” and “retardation” 
showed a similar progressive reduction throughout the study. 
The rate of decrease of the two items was approximately 
parallel (Figure 2). At the end of the study anxiety was reduced 
by 82% and retardation by 88%. The anxiety/retardation ratio 
remained essentially constant during milnacipran therapy 
confirming the absence of any “activation syndrome”.10
Adverse events
Adverse events (AEs) with milnacipran therapy were 
scored with the UKU Side Effect Rating in all patients. 
A total of 48 AEs were recorded during the study (Table 4). 
No AE was scored with a severity rating greater than 2, 
indicating that they did not significantly affect the patients’ 
daily life. The most frequent AEs, which occurred in more 
than 5 patients, were nausea, anxiety, tachycardia and 
dizziness. The majority of AEs occurred within the first 
week of treatment with milnacipran and tended to resolve 
spontaneously from the beginning of the second week. 
Seventy percent of all AEs had resolved by the third week 
of treatment.
Discussion
The cohort of the present study was a relatively classi-
cal mild to moderately depressed population although 
the proportion of women (86%) was somewhat higher 
Table 2 suicidality (thoughts and behavior) reported during the 
study
Number 
of patients 
reporting
% of all suicidal 
thoughts and 
behavior
inanity of existence thoughts 11 19.4
Thoughts of death 9 15.8
suicidal thoughts 7 12.3
Unwillingness to live 6 10.5
Visualizations of suicide 5 8.8
Visualizations of death 4 7
Visualizations of funerals 4 7
Death instinct 4 7
suicidal compulsive thoughts 2 3.5
Funerals compulsive thoughts 2 3.5
suicidal fantasies 2 3.5
Death compulsive thoughts 1 1.7
Total occurrences of suicidal 
thoughts or behaviora
57 100
asome patients reported more than one suicidal manifestation.
Table 3 evolution of mean global Beck scale for suicidal ideation 
scores during the study
Mean (SD) Pa
Baseline 4.87 (4.91)
Week 1 4.52 (4.38) Ns
Week 2 2.00 (2.83) 0.008
Week 3 1.10 (2.10) 0.0007
Week 4 0.20 (0.33) 0.0001
Week 5 0.10 (0.33) 0.0001
Week 6 0.10 (0.33) 0.0001
aSignificance compared to baseline values.Neuropsychiatric Disease and Treatment 2009:5 419
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than that commonly reported. At baseline nearly 50% of 
patients reported some form of suicidal ideation although 
none reported previous suicidal attempts, planning or 
preparation. Almost all of the suicidal manifestations 
observed during the study were limited to the cogni-
tive sphere (thoughts, concepts). In addition, in the 
majority of cases, suicidal manifestations occurred only 
occasionally, and the suicidal fantasies, reported in only 
2 patients, were transient (up to 1 to 2 hours per day over 
several days).
The wide prevalence of different suicidal manifestations 
in patients with mild to moderate depressive disorders shown 
here is important since, even in absence of a behavioral 
component they are considered to be a potent predictor of 
future suicidal behavior.2,13,23
Regular patient assessment with HDRS17, CGI and BDI 
showed a progressive regression of depressive symptoms 
throughout the study. There were few AEs, all of them mild 
as assessed by the UKU Side Effect Rating. Only one patient 
withdrew because of side effects.
The progressive regression of suicidal thoughts during 
milnacipran therapy observed at weekly testing showed no 
enhancement of suicidal risk at early stages of antidepres-
sant pharmacotherapy. On the contrary, the administration of 
milnacipran led to a progressive and almost total reduction of 
all suicidal manifestations. The drug’s effects on important 
aspects of the clinical profile of depression such as anxiety 
and retardation appeared to be well balanced. This may have 
contributed to the lack of “activation syndrome” which has 
been associated increased suicide risk.10 Even the occurrence 
of AEs such as anxiety during milnacipran therapy did not 
negatively affect the general suicidality of patients.
This study suffers from several weaknesses, namely 
the small cohort studied, its open nature and the relatively 
short observation period (6 weeks). To our knowledge this 
is the first study to have analyzed suicidality and depressive 
symptoms in parallel during the treatment with milnacipran. 
A meta-analysis of suicidal behaviors and ideation in clinical 
trials in depression with another SNRI, duloxetine, has also 
demonstrated the absence of increased risk of suicidal behav-
iors or ideation during treatment with the SNRI compared 
with placebo.24
From this small open study there is a clear suggestion 
that mild suicidal thoughts can be relatively common 
even in mild to moderately depressed patients. During 
treatment with milnacipran suicidal thoughts regressed 
progressively in parallel with other depressive symptoms. 
At no time was there any noticeable increase in suicidal 
thoughts even in patients who reported anxiety as an 
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Figure 2 Reduction of mean “anxiety” and “retardation” scores during the study.
Notes: “Anxiety” was the score of item 10 of the hDRs17. “Retardation” was the 
score of item 8 of the hDRs17.
Abbreviations: B, baseline; W1 to W6, number of weeks of treatment; solid line, 
“anxiety” item; broken line, “retardation” item. 
Table 4 Adverse events
Number of adverse events recorded
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
Number of patients 29 29 29 28 28 28
Nausea 15 10 2 0 0 0
Anxiety 10 7 5 2 2 2
Tachycardia 8 5 1 0 0 0
Dizziness 7 3 0 0 0 0
sweating 5 5 5 4 2 1
somnolence 2 2 0 0 0 0
Abnormal ejaculation 1 1 1 1 0 0
Total number of adverse events 48 33 14 7 4 3Neuropsychiatric Disease and Treatment 2009:5
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adverse event. This study clearly warrants replication 
in a larger cohort which should be followed for a longer 
period of time.
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